|
Hisamitsu Pharmaceutical Co., Inc. (4530.T) Avaliação DCF
JP | Healthcare | Drug Manufacturers - Specialty & Generic | JPX
|
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Hisamitsu Pharmaceutical Co., Inc. (4530.T) Bundle
Aproveite a oportunidade de aprimorar sua análise de avaliação Hisamitsu Pharmaceutical Co., Inc. (4530T) usando nossa sofisticada calculadora DCF! Este modelo do Excel é pré -carregado com dados reais (4530T), permitindo que você ajuste as previsões e suposições para determinar com precisão o valor intrínseco da Hisamitsu Pharmaceutical Co., Inc.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 140,992.0 | 114,510.0 | 120,193.0 | 128,330.0 | 141,706.0 | 142,901.1 | 144,106.2 | 145,321.5 | 146,547.0 | 147,782.9 |
| Revenue Growth, % | 0 | -18.78 | 4.96 | 6.77 | 10.42 | 0.84333 | 0.84333 | 0.84333 | 0.84333 | 0.84333 |
| EBITDA | 26,980.0 | 14,751.0 | 13,658.0 | 16,553.0 | 24,374.0 | 21,000.8 | 21,177.9 | 21,356.5 | 21,536.6 | 21,718.2 |
| EBITDA, % | 19.14 | 12.88 | 11.36 | 12.9 | 17.2 | 14.7 | 14.7 | 14.7 | 14.7 | 14.7 |
| Depreciation | 4,251.0 | 4,079.0 | 4,321.0 | 4,952.0 | 5,172.0 | 5,053.2 | 5,095.8 | 5,138.8 | 5,182.2 | 5,225.9 |
| Depreciation, % | 3.02 | 3.56 | 3.6 | 3.86 | 3.65 | 3.54 | 3.54 | 3.54 | 3.54 | 3.54 |
| EBIT | 22,729.0 | 10,672.0 | 9,337.0 | 11,601.0 | 19,202.0 | 15,947.6 | 16,082.1 | 16,217.7 | 16,354.5 | 16,492.4 |
| EBIT, % | 16.12 | 9.32 | 7.77 | 9.04 | 13.55 | 11.16 | 11.16 | 11.16 | 11.16 | 11.16 |
| Total Cash | 141,929.0 | 135,997.0 | 142,431.0 | 136,868.0 | 125,321.0 | 139,596.4 | 140,773.7 | 141,960.9 | 143,158.1 | 144,365.4 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 48,907.0 | 39,203.0 | 38,112.0 | 39,753.0 | 42,983.0 | 46,283.3 | 46,673.7 | 47,067.3 | 47,464.2 | 47,864.5 |
| Account Receivables, % | 34.69 | 34.24 | 31.71 | 30.98 | 30.33 | 32.39 | 32.39 | 32.39 | 32.39 | 32.39 |
| Inventories | 15,458.0 | 18,568.0 | 16,412.0 | 18,922.0 | 21,176.0 | 20,155.3 | 20,325.3 | 20,496.7 | 20,669.6 | 20,843.9 |
| Inventories, % | 10.96 | 16.22 | 13.65 | 14.74 | 14.94 | 14.1 | 14.1 | 14.1 | 14.1 | 14.1 |
| Accounts Payable | 10,488.0 | 7,672.0 | 7,533.0 | 8,351.0 | 16,263.0 | 10,971.9 | 11,064.5 | 11,157.8 | 11,251.9 | 11,346.8 |
| Accounts Payable, % | 7.44 | 6.7 | 6.27 | 6.51 | 11.48 | 7.68 | 7.68 | 7.68 | 7.68 | 7.68 |
| Capital Expenditure | -3,726.0 | -3,388.0 | -4,193.0 | -7,908.0 | -13,036.0 | -6,988.3 | -7,047.2 | -7,106.7 | -7,166.6 | -7,227.0 |
| Capital Expenditure, % | -2.64 | -2.96 | -3.49 | -6.16 | -9.2 | -4.89 | -4.89 | -4.89 | -4.89 | -4.89 |
| Tax Rate, % | 27.19 | 27.19 | 27.19 | 27.19 | 27.19 | 27.19 | 27.19 | 27.19 | 27.19 | 27.19 |
| EBITAT | 16,245.3 | 8,093.5 | 6,960.2 | 8,454.0 | 13,980.6 | 11,722.7 | 11,821.5 | 11,921.2 | 12,021.8 | 12,123.2 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -37,106.7 | 12,562.5 | 10,196.2 | 2,165.0 | 8,544.6 | 2,216.9 | 9,402.4 | 9,481.7 | 9,561.6 | 9,642.3 |
| WACC, % | 7.89 | 7.89 | 7.89 | 7.89 | 7.89 | 7.89 | 7.89 | 7.89 | 7.89 | 7.89 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 31,330.7 | |||||||||
| Long Term Growth Rate, % | 3.50 | |||||||||
| Free cash flow (T + 1) | 9,980 | |||||||||
| Terminal Value | 227,104 | |||||||||
| Present Terminal Value | 155,322 | |||||||||
| Enterprise Value | 186,652 | |||||||||
| Net Debt | -110,359 | |||||||||
| Equity Value | 297,011 | |||||||||
| Diluted Shares Outstanding, MM | 77 | |||||||||
| Equity Value Per Share | 3,857.14 |
What You Will Receive
- Adjustable Forecast Inputs: Effortlessly modify key assumptions (growth %, profit margins, WACC) to explore various scenarios.
- Comprehensive Financial Data: Hisamitsu Pharmaceutical’s financial information pre-filled to kickstart your analysis.
- Automated DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value automatically.
- Customizable and Professional Design: A sleek Excel model tailored to fit your valuation requirements.
- Designed for Analysts and Investors: Perfect for evaluating projections, validating strategies, and enhancing efficiency.
Key Features
- Accurate Hisamitsu Financial Data: Gain access to reliable historical data and future forecasts pre-loaded for your convenience.
- Customizable Forecast Inputs: Modify highlighted cells to adjust factors like WACC, growth rates, and profit margins as needed.
- Real-Time Calculations: Enjoy automatic updates for DCF, Net Present Value (NPV), and comprehensive cash flow analyses.
- User-Friendly Dashboard: Intuitive charts and summaries that help you easily visualize your valuation outcomes.
- Suitable for All Levels: Designed with a straightforward layout to accommodate investors, CFOs, and consultants alike.
How It Functions
- Download the Template: Gain immediate access to the Excel-based Hisamitsu Pharmaceutical DCF Calculator.
- Input Your Assumptions: Modify yellow-highlighted cells for growth rates, WACC, profit margins, and more.
- Instant Calculations: The model automatically recalculates the intrinsic value of Hisamitsu Pharmaceutical (4530T).
- Test Scenarios: Experiment with various assumptions to assess potential changes in valuation.
- Analyze and Decide: Utilize the findings to inform your investment or financial analysis.
Why Choose This Calculator for Hisamitsu Pharmaceutical Co., Inc. (4530T)?
- Designed for Experts: A sophisticated tool tailored for analysts, CFOs, and consultants.
- Accurate Data: Hisamitsu's historical and projected financials are preloaded for precise calculations.
- Flexible Scenario Analysis: Effortlessly simulate various forecasts and assumptions.
- Comprehensive Outputs: Automatically computes intrinsic value, NPV, and essential metrics.
- User-Friendly: Step-by-step guidance ensures a smooth user experience.
Who Can Benefit from This Product?
- Investors: Precisely assess the fair value of Hisamitsu Pharmaceutical Co., Inc. (4530T) prior to making investment choices.
- CFOs: Utilize a top-tier DCF model for comprehensive financial reporting and analysis.
- Consultants: Seamlessly customize the template for client valuation reports.
- Entrepreneurs: Acquire knowledge of financial modeling practices utilized by leading pharmaceutical companies.
- Educators: Employ it as an educational resource to illustrate various valuation techniques.
What the Template Contains
- Historical Data: Contains Hisamitsu Pharmaceutical's past financials and baseline forecasts.
- DCF and Levered DCF Models: Comprehensive templates to assess the intrinsic value of Hisamitsu Pharmaceutical (4530T).
- WACC Sheet: Pre-configured calculations for the Weighted Average Cost of Capital.
- Editable Inputs: Customize essential drivers such as growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A thorough analysis of Hisamitsu Pharmaceutical's financials.
- Interactive Dashboard: Dynamically visualize valuation results and projections.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.